文献速递皮肤肿瘤

原发皮肤T滤泡辅助表型外周T细胞淋巴瘤:整合临床、病理与分子特征的病例系列研究

Primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype: an integrative clinical, pathological and molecular case series study.
PubMed 文献 · Br J Dermatol · 2022-09-02

该研究纳入23例原发皮肤T滤泡辅助表型外周T细胞淋巴瘤(pcTFH-PTCL)患者,中位年龄66岁,均以皮肤病变起病且无系统性疾病。多数为T3b期,病理示CD4+ T细胞增殖表达至少两种TFH标记,8例伴B细胞淋巴增殖性疾病。3例(13%)发生系统性疾病并死于淋巴瘤。

要点

  • pcTFH-PTCL患者多数病变局限于皮肤,仅3例(13%)出现系统播散并死亡。
  • 病理示CD4+ T细胞增殖,常位于真皮深层,表达至少两种TFH标记(CD10、CXCL13、PD1、ICOS、BCL6)。
  • 8例活检诊断伴B细胞淋巴增殖性疾病,包括EBV阳性弥漫大B细胞淋巴瘤3例、EBV阳性LPD 1例、单型浆细胞LPD 4例。

核心结论

  • pcTFH-PTCL的病理和遗传特征与TFH来源的系统性淋巴瘤重叠,但临床上多数局限于皮肤,仅3例出现系统播散和死亡。
  • pcTFH-PTCL是否应作为TFH淋巴瘤的新亚组纳入未来分类仍存争议。

研究设计与样本

  • 回顾性分析23例原发皮肤T滤泡辅助表型外周T细胞淋巴瘤(pcTFH-PTCL)患者的临床和病理资料,并对活检样本进行靶向二代测序。

主要发现

  • 所有患者(15男8女,中位年龄66岁)均以皮肤病变起病,无系统性疾病;多数为T3b期,皮损呈结节状(16例)、丘疹状(6例)或斑块状(非典型MF,1例)。
  • 3例(13%)发生系统性疾病并死于淋巴瘤;9例(39%)接受超过一线化疗。
  • 组织学示CD4+ T细胞增殖,常密集位于真皮深层(14例,61%),表达至少两种TFH标记(CD10、CXCL13、PD1、ICOS、BCL6),其中16例(70%)表达三种标记。
  • 8例活检诊断伴B细胞淋巴增殖性疾病:EBV阳性弥漫大B细胞淋巴瘤(3例)、EBV阳性LPD(1例)、单型浆细胞LPD(4例)。
  • 靶向测序示4例存在TET2-RHOAG17V联合突变,另1例为TET2/DNMT3A/PLCG1/SETD2突变谱;后者、1例TET2-RHOA联合突变者及1例未检出突变者发生系统性疾病并死亡;另5例分别见TET2(1例)、PLCG1(2例)、SETD2(1例)或STAT5B(1例)孤立突变。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype (pcTFH-PTCL) are poorly characterized, and often compared to, but not corresponding with, mycosis fungoides (MF), Sézary syndrome, primary cutaneous CD4+ lymphoproliferative disorder, and skin manifestations of angioimmunoblastic T-cell lymphomas (AITL). OBJECTIVES: We describe the clinicopathological features of pcTFH-PTCL in this original series of 23 patients, and also characterize these cases molecularly. METHODS: Clinical and histopathological data of the selected patients were reviewed. Patient biopsy samples were also analysed by targeted next-generation sequencing. RESULTS: All patients (15 men, eight women; median age 66 years) presented with skin lesions, without systemic disease. Most were stage T3b, with nodular (n = 16), papular (n = 6) or plaque (atypical for MF, n = 1) lesions. Three (13%) developed systemic disease and died of lymphoma. Nine (39%) patients received more than one line of chemotherapy. Histologically, the lymphomas were CD4+ T-cell proliferations, usually dense and located in the deep dermis (n = 14, 61%), with the expression of at least two TFH markers (CD10, CXCL13, PD1, ICOS, BCL6), including three markers in 16 cases (70%). They were associated with a variable proportion of B cells. Eight patients were diagnosed with an associated B-cell lymphoproliferative disorder (LPD) on biopsy, including Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (n = 3), EBV+ LPD (n = 1) and monotypic plasma cell LPD (n = 4). Targeted sequencing showed four patients to have a mutated TET2-RHOAG17V association (as frequently seen in AITL) and another a TET2/DNMT3A/PLCG1/SETD2 mutational profile. The latter patient, one with a TET2-RHOA association, and one with no detected mutations, developed systemic disease and died. Five other patients showed isolated mutations in TET2 (n = 1), PLCG1 (n = 2), SETD2 (n = 1) or STAT5B (n = 1). CONCLUSIONS: Patients with pcTFH-PTCL have pathological and genetic features that overlap with those of systemic lymphoma of TFH derivation. Clinically, most remained confined to the skin, with only three patients showing systemic spread and death. Whether pcTFH-PTCL should be integrated as a new subgroup of TFH lymphomas in future classifications is still a matter of debate. What is already known about this topic? There is a group of cutaneous lymphomas that express T-follicular helper (TFH) markers that do not appear to correspond to existing World Health Organization diagnostic entities. These include mycosis fungoides, Sézary syndrome, or primary cutaneous CD4+ small/medium-sized T-cell lymphoproliferative disorder or cutaneous extensions of systemic peripheral T-cell lymphomas (PTCL) with TFH phenotype. What does this study add? This is the first large original series of patients with a diagnosis of primary cutaneous PTCL with a TFH phenotype (pcTFH-PTCL) to be molecularly characterized. pcTFH-PTCL may be a standalone group of cutaneous lymphomas with clinicopathological and molecular characteristics that overlap with those of systemic TFH lymphomas, such as angioimmunoblastic T-cell lymphoma, and does not belong to known diagnostic groups of cutaneous lymphoma. This has an impact on the treatment and follow-up of patients; the clinical behaviour needs to be better clarified in further studies to tailor patient management.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Wang L, Rocas D, Dalle S, et al. Primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype: an integrative clinical, pathological and molecular case series study. Br J Dermatol. 2022. PMID: 35895386. doi:10.1111/bjd.21791

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。